RAOUL RADU SALUP
Medical Practice in Tampa, FL
License number
Pennsylvania MD035935E
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Tampa, FL 33609
Pennsylvania
Pennsylvania
Personal information
See more information about RAOUL RADU SALUP at radaris.comName
Address
Phone
5016 Evelyn Dr, Tampa, FL 33609
607 Tropical Breeze Way, Tampa, FL 33602
Professional information
Raoul Salup, Tampa FL
Work:
James A. Haley Veterans Medical Center
13000 Bruce B Downs Blvd, Tampa, FL 33612
13000 Bruce B Downs Blvd, Tampa, FL 33612
Dr. Raoul R Salup - MD (Doctor of Medicine)
Specialties:
Urology
Certifications:
Urology, 2013
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Comprehensive Breast Center
4306 Alton Rd, Miami Beach 33140
James A Haley VA Hospital GNS
13000 Bruce B Downs Blvd, Tampa 33612
Comprehensive Breast Center
4306 Alton Rd, Miami Beach 33140
James A Haley VA Hospital GNS
13000 Bruce B Downs Blvd, Tampa 33612
4306 Alton Rd, Miami Beach 33140
James A Haley VA Hospital GNS
13000 Bruce B Downs Blvd, Tampa 33612
Comprehensive Breast Center
4306 Alton Rd, Miami Beach 33140
James A Haley VA Hospital GNS
13000 Bruce B Downs Blvd, Tampa 33612
Education:
Medical School
Philipps-Universitaet Marburg, Fachbereich Medizin
Graduated: 1980
City Hospital
Graduated: 1981
Johns Hopkins University
Graduated: 1983
University Pittsburgh Hosps
Graduated: 1992
National Cancer Institute
Graduated: 1986
Philipps-Universitaet Marburg, Fachbereich Medizin
Graduated: 1980
City Hospital
Graduated: 1981
Johns Hopkins University
Graduated: 1983
University Pittsburgh Hosps
Graduated: 1992
National Cancer Institute
Graduated: 1986
Prostate Carcinogenesis Predictor
US Patent:
2014006, Mar 6, 2014
Filed:
Nov 8, 2013
Appl. No.:
14/075814
Inventors:
Hla Y. WIN - Tampa FL, US
Raoul SALUP - Tampa FL, US
Raoul SALUP - Tampa FL, US
Assignee:
The United States Government as represented by the Department of Veterans Affairs - Washington DC
UNIVERSITY OF SOUTH FLORIDA - Tampa FL
UNIVERSITY OF SOUTH FLORIDA - Tampa FL
International Classification:
A61K 31/713, G01N 33/574, A61K 31/675
US Classification:
424450, 514 44 A, 514 94, 435375, 435 71
Abstract:
A method of detecting prostate tumorigenesis in a subject, the method including the steps of (a) obtaining a sample from the prostate of the human subject, (b) detecting quantitatively or semi-quantitatively in the sample a level of expression for PKC-ι and (c) comparing the expression level in (b) to a level of expression in a normal control, wherein overexpression of PKC-ι, with respect to the control, indicates the presence of prostate cancer in the subject. The present invention is based upon the discovery that PKC-ι levels are elevated during prostate tumorigenesis. Furthermore, the proliferation rate of the tumor correlates with the level of PKC-ι. The invention also provides methods of treating prostate cancer by administering to the subject a compound that inhibits the expression of PKC-ι. The compound can be a small interfering RNA (siRNA) molecule.
Prostate Carcinogenesis Predictor
US Patent:
2012029, Nov 22, 2012
Filed:
Jun 25, 2012
Appl. No.:
13/532364
Inventors:
Hla Y. Win - Tampa FL, US
Raoul Salup - Tampa FL, US
Raoul Salup - Tampa FL, US
Assignee:
University of South Florida - Tampa FL
International Classification:
G01N 33/574, C12Q 1/68, G01N 21/64, G01N 21/76, A61K 31/675, A61K 31/713, A61K 9/127, A61K 9/133, A61P 35/00, C12N 5/09, G01N 33/577
US Classification:
424450, 435375, 435 74, 435 611, 435 612, 514 44 A, 514 94
Abstract:
A method of detecting prostate tumorigenesis in a subject, the method including the steps of (a) obtaining a sample from the prostate of the human subject, (b) detecting quantitatively or semi-quantitatively in the sample a level of expression for PKC-ι and (c) comparing the expression level in (b) to a level of expression in a normal control, wherein overexpression of PKC-ι, with respect to the control, indicates the presence of prostate cancer in the subject. The present invention is based upon the discovery that PKC-ι levels are elevated during prostate tumorigenesis. Furthermore, the proliferation rate of the tumor correlates with the level of PKC-ι. The invention also provides methods of treating prostate cancer by administering to the subject a compound that inhibits the expression of PKC-ι. The compound can be a small interfering RNA (siRNA) molecule.
Prostate Carcinogenesis Predictor
US Patent:
2009013, May 21, 2009
Filed:
Oct 17, 2008
Appl. No.:
12/253663
Inventors:
Hla Y. Win - Tampa FL, US
Raoul Salup - Tampa FL, US
Raoul Salup - Tampa FL, US
International Classification:
A61K 9/127, G01N 33/53, G01N 33/535, A61P 35/00, C12Q 1/68, A61K 31/7105
US Classification:
424450, 435 71, 435 792, 435 6, 514 44
Abstract:
A method of detecting prostate tumorigenesis in a subject, the method including the steps of (a) obtaining a sample from the prostate of the human subject, (b) detecting quantitatively or semi-quantitatively in the sample a level of expression for PKC-ι and (c) comparing the expression level in (b) to a level of expression in a normal control, wherein overexpression of PKC-ι, with respect to the control, indicates the presence of prostate cancer in the subject. The present invention is based upon the discovery that PKC-ι levels are elevated during prostate tumorigenesis. Furthermore, the proliferation rate of the tumor correlates with the level of PKC-ι. The invention also provides methods of treating prostate cancer by administering to the subject a compound that inhibits the expression of PKC-ι. The compound can be a small interfering RNA (siRNA) molecule.